Hepatology(Liver, Pancreatic, Gall Bladder)

  • Home
  • Hepatology(Liver, Pancreatic, Gall Bladder)
Bile Composition in Healthy and Gallstones Patients

Conditions:   Cholelithiasis;   Gall Stone;   Gall Bladder Disease
Interventions:   Diagnostic Test: Bile test;   Diagnostic Test: Blood test;   Diagnostic Test: Gall stone study;   Diagnostic Test: Microbiological bile test
Sponsor:   Hospital Son Espases
Not yet recruiting
ClinicalTrials.gov: Gall Bladder | Recruiting, Not yet recruiting, Available Studies | First posted in the last 100 days

June 10, 2019Comments OffBile | Composition | Gallstones | Healthy | Patients
Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Conditions:   Borderline Resectable Pancreatic Adenocarcinoma;   Resectable Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Fluorouracil;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Biological: Nivolumab;   Drug: Oxaliplatin;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2019Comments OffBefore | Borderline | Cancer | Chemotherapy | Combination | Nivolumab | Pancreatic | Patients | Resectable | Surgery | Treating
Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism

Conditions:   Healthy;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019Comments OffCarbohydrate | Diets | Effects | Energy | Metabolism | Versus
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Conditions:   Pancreatic Ductal Adenocarcinoma (PDAC);   Cancer of Pancreas;   Pancreatic Cancer, Adult;   Pancreas Adenocarcinoma;   Pancreatic Neoplasms;   Pancreatic Cancer Non-resectable;   Pancreatic Cancer Resectable
Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan Hydrochloride;   Drug: 5-FU
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019Comments OffCancer | FOLFIRINOX | Nonmetastatic | Pancreatic | Subjects | Subtypes | Tumor
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

Condition:   Healthy Participants
Intervention:   Drug: Glucagon
Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019Comments OffAssessed | Effect | Glucagon | Hepatic | Mitochondrial | Oxidation | PINTA | Rates
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients With Cirrhosis Undergoing TIPS Placement

Conditions:   Cirrhosis, Liver;   Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Intervention:  
Sponsors:   Northwestern University;   University of California, San Francisco;   Scripps Health;   University of Wisconsin, Madison;   University of Florida;   University of Arizona;   Stanford University;   Columbia University;   Weill Medical College of Cornell University;   Baylor Scott and White Health;   Mayo Clinic
Not yet recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 5, 2019Comments Off5year | ALTA | Cirrhosis | Longitudinal | Observational | Patients | Placement | Study | TIPS | Undergoing
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer Non-resectable
Interventions:   Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel;   Drug: Placebo + Gemcitabine + Nab-paclitaxel
Sponsor:   FibroGen
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 4, 2019Comments OffAdvanced | Cancer | Chemotherapy | Combination | Efficacy | Evaluation | Gemcitabine | Locally | Nabpaclitaxel. | NEOADJUVANT | Pamrevlumab | Pancreatic | Safety | Treatment
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Conditions:   Cancer of the Prostate;   Castration-resistant Prostate Cancer
Intervention:   Drug: Gadoxetate Sodium
Sponsor:   University of Cincinnati
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019Comments OffAggressive | Biomarker | Cancer | Enhanced | Gadoxetate | Prostate | Sodium
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Conditions:   Hepatic Impairment;   Healthy Participants
Intervention:   Drug: Linzagolix
Sponsor:   ObsEva SA
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019Comments OffFemale | Function | Hepatic | Impaired | Linzagolix | Normal | Pharmacokinetics | Safety | Study | Subjects